Form 4: Athira Pharma CMO Reports Routine Equity Vesting and Tax-Related Stock Sale

Athira Pharma's Chief Medical Officer, Javier San Martin, reported the vesting of Restricted Stock Units and a subsequent non-discretionary sale of shares to cover tax obligations.

Summary

• Javier San Martin, Chief Medical Officer of Athira Pharma, Inc. (ATHA), reported transactions related to his equity holdings.
• On June 30, 2025, 46,666 Restricted Stock Units (RSUs) vested and converted into an equal number of common shares.
• Following this vesting, San Martin beneficially owned 82,507 shares of common stock.
• On July 1, 2025, 10,842 shares of common stock were sold at a weighted-average price of $0.2935 per share.
• This sale was non-discretionary, executed to cover tax withholding and remittance obligations associated with the RSU vesting, pursuant to the issuer's mandatory 'sell to cover' policies.
• The shares sold ranged in price from $0.2854 to $0.3031.
• After these transactions, San Martin beneficially owns 71,665 shares of common stock.
• Additionally, 46,667 Restricted Stock Units remain beneficially owned, representing the final tranche of a 140,000 RSU grant from October 1, 2024, set to vest on December 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the transaction itself is a routine, non-discretionary event (vesting and tax-related sale), the very low share price at which the sale occurred introduces a negative undertone regarding the company's current valuation.

Positives

• The vesting of Restricted Stock Units represents a scheduled component of executive compensation, indicating the fulfillment of equity incentive plan terms.
• The transaction was non-discretionary, a 'sell to cover' for tax purposes, rather than a voluntary sale by the executive, which typically signals confidence in the company.

Negatives

• The weighted-average sale price of $0.2935 per share is very low, reflecting a significantly depressed stock valuation for Athira Pharma.
• The sale, even if for tax purposes, reduces the direct shareholding of a key executive.

Risks

• The low share price at which the shares were sold ($0.2935) indicates potential ongoing valuation challenges or market skepticism regarding Athira Pharma's prospects.
• Future stock price volatility could impact the value of the remaining unvested RSUs and the executive's overall compensation.

Future Outlook

The remaining 46,667 Restricted Stock Units are scheduled to vest on December 31, 2025, contingent on the reporting person's continued service as a Service Provider.

Management Comments

• The sale of common stock was executed to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units, pursuant to mandatory 'sell to cover' policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person.

Industry Context

This Form 4 filing details a routine executive equity compensation event common in publicly traded companies, particularly those in the biotechnology sector like Athira Pharma. The low share price at the time of the 'sell to cover' transaction highlights the current valuation challenges faced by the company, which may be indicative of broader market sentiment towards early-stage biotech firms or specific company-related developments.

Comparison to Industry Standards

• Executive equity compensation, including Restricted Stock Units (RSUs) and 'sell to cover' tax policies, is a standard practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, aligning with common industry benchmarks for executive incentive structures.
• The weighted-average sale price of $0.2935 per share is significantly below typical share prices for established public companies, which could indicate a valuation challenge for Athira Pharma relative to its industry peers, although direct comparisons to specific companies' share prices are not provided in this filing.

Related Party Transactions

• The vesting of Restricted Stock Units and the subsequent sale of shares to cover tax obligations represent transactions between the company (issuer) and a key executive (reporting person), which are considered related-party transactions as part of executive compensation.

Stakeholder Impact

• Shareholders gain insight into executive compensation and equity holdings, noting a routine vesting and a non-discretionary sale for tax purposes.
• Employees may view the vesting as a positive sign of compensation plans being executed as scheduled.

Next Steps

• The final one-third tranche of the 140,000 RSUs granted on October 1, 2024, is scheduled to vest on December 31, 2025, subject to continued service.

Key Dates

Keywords

Form 4, SEC filing, insider transaction, Restricted Stock Units, RSU vesting, equity compensation, sell to cover, Athira Pharma, ATHA, Chief Medical Officer, stock sale, corporate governance